Drugs / APAC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07352800 | Jan 2026 → Jun 2027 expected | limb ischemia, peripheral arterial disease | Aplagon Oy | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-01 | Aplagon Oy | Results Aplagon Publishes New Data in Prestigious Journal of Cardiovascular Pharmacology aplagon.com ↗
The results indicate that APAC is safe, targeted, has a rapid onset of action, and does not accumulate after repeat dosing. |
All press releases naming this drug 8 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07352800 ↗ |
| Route | Intravenous | “a single dose will be administered intravenously (i.v.)” NCT07352800 ↗ |